BridgeBio Pharma (BBIO) Soars 17.1%: Is Further Upside Left in the Stock?

BridgeBio Pharma (BBIO) shares ended the last trading session 17.1% higher at $63.56. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 8.4% gain over the past four weeks.

The stock rallied after the company announced positive top-line data from the pivotal phase III FORTIFY study evaluating BBP-418 in people living with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The study achieved all primary and secondary interim analysis endpoints. Treatment with BBP-418 was well-tolerated with no new or unexpected safety findings reported. BridgeBio plans to submit a new drug application for BBP-418 in the first half of 2026.

This rare disease drug developer is expected to post quarterly loss of $0.88 per share in its upcoming report, which represents a year-over-year change of -2.3%. Revenues are expected to be $105.47 million, up 3763.3% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For BridgeBio Pharma, the consensus EPS estimate for the quarter has been revised 3.1% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on BBIO going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

BridgeBio Pharma is part of the Zacks Medical - Generic Drugs industry. Supernus Pharmaceuticals (SUPN), another stock in the same industry, closed the last trading session 0.2% lower at $52.72. SUPN has returned 12.3% in the past month.

For Supernus, the consensus EPS estimate for the upcoming report has changed +14.3% over the past month to $0.3. This represents a change of -71.7% from what the company reported a year ago. Supernus currently has a Zacks Rank of #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research